Eli Lilly (NYSE:LLY) recently announced promising Phase 1 data for its folate receptor alpha antibody-drug conjugate, ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

But given Eli Lilly's strong performance thus far and current market share, there's a reason why many investors believe this ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

In this note, we discuss Eli Lilly’s stock performance, key takeaways from its recent results, and valuation. Firstly, let us look at its stock performance. LLY stock has seen extremely strong ...

Through an analysis of Eli Lilly, we can infer the ... which is 3.75x the industry average, the stock might be considered overvalued based on sales performance. With a Return on Equity (ROE ...

The stock carries a hefty premium, but it is justified by the company's growth and the size of the market for GLP-1s. Eli Lilly's Q1 report ... The positive performance was driven by the ...

owing to strong performance from its weight loss drugs. With this type of growth and demand in the forecast, Eli Lilly’s stock price is likely to continue to reflect this bullish momentum ...

Eli Lilly (NYSE: LLY) stock has soared 90% over ... As a result, Lilly's earnings and stock performance have surged. But does this make Lilly the best pharma stock for you? Let's find out.

Eli Lilly’s LLY first-quarter revenue grew 45 ... We think price competition with Novo and other future competitors means non-GAAP performance margin (similar to operating margin) could only ...